RemeGen Ltd.

Less than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company a

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a stron

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included